Richard G.
- Country
- Austria
- Department
- 3rd Medical Department
Research Overview
- A Phase 2/3, Multicenter, Randomized, Dose Optimization (Part I), Double-blind (Part II) Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG®) plus Best Supportive Care (BSC) versus Placebo plus BSC in Participants with IPSS-R Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)
- Safety Study of Ivosidenib in Patients with Pretreated Locally Advanced or Metastatic Cholangiocarcinoma
- Phase 3 Randomized Study of Relatlimab-Nivolumab vs. Regorafenib or Trifluridine/Tipiracil in Late-Line Metastatic Colorectal Cancer
Data & Insights
Has run more than one trial at 227 of 544 partner sites.
Specializations
Hematologic Malignancies
Specializes in investigating novel treatments for various blood cancers, with particular emphasis on multiple myeloma and lymphomas.
- Multiple Myeloma Treatment Innovation
- Diffuse Large B-Cell Lymphoma
- Hodgkin Lymphoma Management
Focuses on evaluating new therapeutic combinations and maintenance strategies following stem cell transplantation.
Solid Tumors
Conducts research on advanced treatment approaches for various solid cancers, with specific interest in breast cancer and cholangiocarcinoma.
- HER2-Positive Breast Cancer
- Metastatic Colorectal Cancer
- Advanced Solid Tumors with Brain Metastases
Investigates targeted therapies and immunotherapy combinations for advanced-stage cancers.
Innovative Therapies
Leads research in cutting-edge therapeutic approaches, including CAR-T cell therapy and targeted molecular treatments.
- Gene-Modified T Cell Therapies
- Novel Antibody-Drug Conjugates
- Immunotherapy Combinations
Evaluates long-term outcomes and safety profiles of advanced cellular therapies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.